

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

CHANGE OF NON-EXECUTIVE DIRECTORS AND AUTHORIZED REPRESENTATIVES

The board (the “**Board**”) of directors (the “**Director(s)**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following change of non-executive Directors.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

Mr. Chen Anhua (“**Mr. Chen**”) had tendered his resignation as a non-executive Director with effect from 14 September 2023, as he desires to devote more time to his other business commitments.

Mr. Chen has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Chen for his contributions to the Group during his tenure of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board also announces that Ms. Jiang Juqi (“**Ms. Jiang**”) has been appointed as a non-executive Director with effect from 14 September 2023.

The biographical details of Ms. Jiang are set out as follows:

Ms. Jiang, 48 years old, is a certified public accountant in China. She graduated from Xiamen University with a bachelor’s degree in economics in 1996 and Jinan University with a master’s degree in economics in 1999.

Ms. Jiang has over 20 years of extensive experience in commercial banking, asset management and investment. From February 2000 to December 2020, she worked in Guangdong Branch of China Great Wall Asset Management Co., Ltd. and held key positions in various departments, including project manager, business supervisor, deputy senior manager and senior manager. Since January 2021, Ms. Jiang has been working for China Great Wall AMC (International) Holdings Co., Ltd. and currently serves as the assistant of general manager of the company. Prior to joining China Great Wall Asset Management Co., Ltd., she worked in the International Business Department of the Agricultural Bank of China Guangdong Branch.

Ms. Jiang has entered into an appointment letter with the Company, pursuant to which she has been appointed as a non-executive Director with effect from 14 September 2023 for a term of three years and which is renewable automatically for a successive term of one year until terminated by either party by giving not less than three months' written notice. Ms. Jiang's directorship will also be subject to retirement by rotation and re-election at the next general meeting of the Company pursuant to the articles of association of the Company. Ms. Jiang is entitled to a Director's fee of HK\$145,000 per annum under the relevant appointment letter as approved by the Board with reference to her qualifications, experience, level of responsibilities undertaken and prevailing market conditions. Save as disclosed above, Ms. Jiang is not entitled to any other emoluments from the Company.

Save as disclosed above and as at the date of this announcement, Ms. Jiang does not (i) have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company (within the meaning of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")); (ii) hold any directorship in other public companies the securities of which are listed in Hong Kong or overseas in the last three years; (iii) hold any other positions within the Company or its subsidiaries; and (iv) have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Save as disclosed above and as at the date of this announcement, the Board is not aware of, and Ms. Jiang confirmed that there are not, any other matters relating to Ms. Jiang's appointment that need to be brought to the attention of the Shareholders nor any information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend a warm welcome to Ms. Jiang for joining the Board.

CHANGE OF AUTHORIZED REPRESENTATIVES

Following the retirement of Mr. Lai Wenjing as an executive Director as disclosed in the announcement of the Company dated 7 September 2023, Mr. Lai Wenjing also ceased to be an authorized representative of the Company (the “**Authorized Representative**”) under Rule 3.05 of the Listing Rules accordingly. Since then, the Company did not comply with the requirement under Rule 3.05 of the Listing Rules that an issuer should appoint two authorized representatives who must be either two Directors or a Director and the company secretary of the Company. To re-comply with Rule 3.05 of the Listing Rules, the Board hereby announces that Ms. Jiang has been appointed as an Authorized Representative with effect from 14 September 2023.

By order of the Board
TATA Health International Holdings Limited

Hong Kong, 14 September 2023

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi and two independent non-executive Directors, namely, Mr. Wang Jian and Ms. Tan Yuying.